🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for TP53 Gene Mutation

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation NCT06908434Phase 11 site📍 Shanghai Changchun GeneScience Pharmaceutical Co., Ltd. · Tests: GenSci128 tablets Clinical and Genetic Studies of Li-Fraumeni Syndrome NCT01443468n/a2 sites📍 Bethesda📍 Bethesda National Cancer Institute (NCI) Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation NCT07499271Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: POLA-R-CHP, Orelabrutinib Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer NCT07198074Phase 3304 sites📍 Birmingham📍 Anchorage📍 Phoenix National Cancer Institute (NCI) · Tests: Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging Study of the Contribution of Mutant p53/YAP Proteins to Therapy Resistance in Recurrent Head and Neck Cancer NCT06791941n/a1 site📍 Roma Regina Elena Cancer Institute · Tests: Culture of organoids Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery NCT02734537Phase 2679 sites📍 Birmingham📍 Anchorage📍 Anchorage ECOG-ACRIN Cancer Research Group · Tests: Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma NCT06136351Phase 21 site📍 Shanghai Ruijin Hospital · Tests: Zanubrutinib, Rituximab, Bendamustin Li-Fraumeni Syndrome/TP53 Biobank NCT04367246n/a2 sites📍 Philadelphia📍 Phildelphia Abramson Cancer Center at Penn Medicine · Tests: No Intervention Oral-ATO for TP53-mutated Myeloid Malignancies NCT06778187Phase 21 site📍 Hong Kong The University of Hong Kong · Tests: Oral arsenic trioxide A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. NCT07372625Phase 15 sites📍 Denver📍 Orlando📍 Nashville PMV Pharmaceuticals, Inc · Tests: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride sy… Combination of CAR-DC Vaccine and ICIs in Malignant Tumors NCT05631886Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide, anti-PD-1 antibody, Anti-CTLA4 Monoclonal Antibody MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam AZA Combined With RCHOP in P53-mutated DLBCL. NCT06158399Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Azacitidine in combination with R-CHOP Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06549790Phase 17 sites📍 Duarte📍 Aurora📍 Newark Nerviano Medical Sciences · Tests: NMS-03597812 Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation NCT06718153NA1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna · Tests: Immunohistochemistry and in situ hybridisation analysis A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation NCT05877599Phase 120 sites📍 Gilbert📍 Duarte📍 Los Angeles AstraZeneca · Tests: NT-175 Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study NCT07242963n/a2 sites📍 Houston📍 Houston Mohammad H. Abu Arja A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies. NCT07017816EARLY Phase 11 site📍 Washington D.C. Children's National Research Institute · Tests: SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC NCT06369181n/a1 site📍 Shanghai Fudan University ALPINE: Maintenance Letrozole/Abemaciclib NCT06366347Phase 28 sites📍 Aurora📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Abemaciclib, Letrozole, Pembrolizumab JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation NCT06386146Phase 1, Phase 215 sites📍 Denver📍 Lake Mary📍 St Louis Jacobio Pharmaceuticals Co., Ltd. · Tests: JAB-30355, JAB-30355 Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress NCT04541654n/a3 sites📍 Boston📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Data and Specimen Collection Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance NCT06043973Phase 31 site📍 Jinan Qianfoshan Hospital · Tests: almonertinib The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study NCT07240194Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Glofitamab, PD-1 Inhibitor, Lenalidomide, Obinutuzumab The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites📍 Irvine📍 La Jolla📍 Los Angeles PMV Pharmaceuticals, Inc · Tests: rezatapopt, pembrolizumab ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL NCT07342478Phase 36 sites📍 Skokie📍 Bethesda📍 Las Vegas Newave Pharmaceutical Inc · Tests: Rocbrutinib, Pirtobrutinib Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer NCT07821879n/a1 site📍 Toulouse Institut Claudius Regaud CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) NCT05143996Phase 1, Phase 217 sites📍 Birmingham📍 Phoenix📍 Duarte Cullinan Therapeutics Inc. · Tests: CLN-049 Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer NCT06413992Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Fluzoparib, Camrelizumab, paclitaxel (albumin bound), Carboplatin injection, Carboplatin A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation NCT07060989Phase 1, Phase 210 sites📍 New Haven📍 Houston📍 Fairfax Nutshell Therapeutics (Shanghai) Co., LTD. · Tests: NTS071
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy